Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 2/20 | 0.53 |
| ▸ | NTSR1 | P30989 | 7/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.51 |
| ▸ | NTSR2 | O95665 | 3/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.50 |
| ▸ | REN | P00797 | 6/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12801509 | 0.97 | NPY1R (0.51) | NPY1RNTSR1OPRD1NTSR2OPRM1 | |
| SCHEMBL12801453 | 0.89 | NPY1R (0.58) | NPY1RNTSR1OPRD1NTSR2OPRM1 | |
| SCHEMBL12801534 | 0.87 | NPY1R (0.63) | NPY1RNTSR1OPRD1NTSR2OPRM1 | |
| SCHEMBL16386324 | 0.87 | OPRD1 (0.57) | NPY1RNTSR1OPRD1NTSR2OPRM1 | |
| SCHEMBL13349129 | 0.87 | OPRD1 (0.57) | NPY1RNTSR1OPRD1NTSR2OPRM1 | |
| SCHEMBL13315205 | 0.86 | NPY1R (0.56) | NPY1RNTSR1OPRD1NTSR2OPRM1 | |
| SCHEMBL16386378 | 0.85 | NPY1R (0.56) | NPY1RNTSR1OPRD1NTSR2OPRM1 | |
| SCHEMBL12801814 | 0.84 | NPY1R (0.54) | NPY1RNTSR1OPRD1NTSR2OPRM1 | |
| SCHEMBL10305285 | 0.84 | OPRD1 (0.55) | NPY1RNTSR1OPRD1NTSR2OPRM1 | |
| SCHEMBL14049654 | 0.82 | NTSR1 (0.56) | NTSR1OPRD1NTSR2OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100143250-A1 | COMPOUNDS FOR THE DIAGNOSIS OF APOPTOSIS | GUERBET (FR) | 2010-06-10 | — | — | US | disclosed |
| US-20100143250-A1 | COMPOUNDS FOR THE DIAGNOSIS OF APOPTOSIS | GUERBET (FR) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100143250-A1 | COMPOUNDS FOR THE DIAGNOSIS OF APOPTOSIS | TPX2, VIP, BAX | NPY1R 191/4885NTSR1 3787/4885OPRD1 3632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.